Roche recently announced positive results from a Phase III GCA clinical trial Fourteenth Breakthrough Therapy designation for Roche medicines There have been no therapies approved for GCA in more than 50 years Basel, 05 October 2016 – Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted […]
Data to be presented today during a late breaking abstract session at the 25th Annual European Academy of Dermatology and Venereology (EADV) Congress Paris, France and Tarrytown, N.Y. (October 1, 2016) – Sanofi and Regeneron Pharmaceuticals, Inc. today announce that detailed results from LIBERTY AD SOLO 1 and SOLO 2, two placebo-controlled Phase 3 studies […]
BLOOMFIELD, Conn, (Sept. 27, 2016) — Global health service company Cigna (NYSE: CI) today announced new, expanded access and choice to affordable telehealth services for millions of Americans enrolled in Cigna administered medical and behavioral health plans for 2017. In 2017, Cigna will significantly expand its telehealth coverage by adding AMWELL (by American Well) to […]
On-Demand, Real-Time Patient Insights and Analytics to Drive High-Value Impact for Telemedicine Visits BOWIE, Md, (Sept. 12, 2016) — Inovalon (NASDAQ: INOV), a leading technology company providing advanced, cloud-based analytics and data-driven intervention platforms to the healthcare industry, today announced a multi-year agreement with MDLIVE, a leading telehealth platform provider, to provide on-demand, real-time patient […]
RALEIGH, N.C. (September 7, 2016) – For more than 45 years, WakeMed Health & Hospitals and the UNC School of Medicine have worked together to teach medical students and residents. This longstanding collaboration continues as WakeMed and the UNC School of Medicine have entered into a new 10-year agreement to provide education and training to […]
Navidea retains rights to non-competitive diagnostic indications and all therapeutic applications DUBLIN, Ohio–(BUSINESS WIRE)–Sep. 6, 2016– Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that it has executed a Letter of Intent (“LOI”) with Cardinal Health, Inc. (NYSE:CAH) for the sale of all rights, title and interest to Navidea’s Lymphoseek product for all FDA-approved, pending and […]
WASHINGTON, Sept. 6, 2016 /PRNewswire/ — Danaher Corporation (NYSE:DHR) (“Danaher” or the “Company”) announced today that it has entered into a definitive merger agreement with Cepheid (NASDAQ:CPHD) pursuant to which Danaher will acquire all of the outstanding shares of Cepheid for $53.00 per share in cash, or a total enterprise value of approximately $4 billion […]
TECENTRIQ showed significant improvement in overall survival for people regardless of their PD-L1 status Data will be discussed with global health authorities, including the U.S. Food and Drug Administration (FDA) September 1, 2016 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results for TECENTRIQ® from the Phase III study, OAK. The study met […]
DUBLIN, Ohio, Aug. 31, 2016 /PRNewswire/ — Non-profit organizations across the country were awarded grants from the Cardinal Health Foundation to help fight prescription drug misuse by improving their communities’ medication disposal programs. According to the 2013 National Survey on Drug Use and Health, nearly 70% of those who misuse prescription drugs get them from […]
XALKORI is the first and only approved biomarker-driven therapy for ROS1-positive advanced NSCLC in the EU Wednesday, August 31, 2016 – “The European Commission’s decision to approve XALKORI for ROS1-positive advanced NSCLC represents an important milestone for patients who previously had limited treatment options” Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved […]
